We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 69

Germany seeks stricter nanomaterial reporting rules under REACH

  • Shook Hardy & Bacon LLP
  • -
  • European Union, Germany
  • -
  • May 10 2013

German safety regulators have apparently sought a major nanotechnologyrelated revision of the European Union's Registration, Evaluation

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Gifts and favours to doctors are not a criminal offence

  • CMS Hasche Sigle
  • -
  • Germany
  • -
  • August 28 2012

The Federal Court of Justice has ruled that it is not a criminal offence for German doctors who have their own practice and are authorised to treat patients insured with a statutory healthcare fund to accept favours or gifts from pharmaceutical companies in return for prescribing particular drugs and medication

Ban on embryonic stem cell patenting in Europe Court of Justice rules on meaning of "human embryo" in stem cells debate

  • Hogan Lovells
  • -
  • European Union, Germany
  • -
  • October 25 2011

The Court of Justice of the European Union (CJEU) handed down its long-awaited judgment in the Brüstle case on the patentability of stem cell inventions

An end to free pricing in the German pharmaceuticals market

  • McDermott Will & Emery
  • -
  • Germany
  • -
  • November 22 2010

Germany has long been the only country in Europe that allows pharmaceutical producers to determine freely their prices for new, supposedly innovative products

German Supreme Court finally finds patent on embryonic stem cell technology valid under reasonable terms while the position of the EPO is still open

  • Prüfer & Partner GbR
  • -
  • European Union, Germany
  • -
  • February 1 2013

Following the preliminary ruling of the Court of Justice of the European Union (CJEU; case C-3410), the long awaited final decision of the German

AG opinion on medical devices qualification issues for e-health software products

  • CMS Cameron McKenna
  • -
  • European Union, Germany
  • -
  • May 21 2012

On 15 May 2012, the Advocate General published his Opinion in the European Court of Justice reference in Brain Products GmbH v BioSemi VOF and Others by the German Supreme Court (Bundesgerichtshof

Risk-sharing and other new business models for pharmaceutical companies in Germany

  • Hogan Lovells
  • -
  • Germany
  • -
  • August 31 2008

The German Federal Law to Increase Competition among Statutory Health Insurance Funds from April 1, 2007 has ushered in major changes regarding the way pharmaceutical companies do business in Germany

FSC decides on patentability of neural progenitor cells II (Brustle)

  • Bird & Bird
  • -
  • Germany
  • -
  • February 25 2013

Recently, the German Federal Supreme Court decided on a nullity action on the patentability of progenitor cells extracted from human embryonic stem

Stricter legislation on corruption in healthcare looming

  • Squire Sanders
  • -
  • Germany
  • -
  • March 22 2013

For years there has been a public debate in Germany about corruption in the healthcare sector - not least because of the huge economical detriments

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy